| Dr Janet Cash, MD | |
|
833 Saint Vincents Dr Ste 300, Pob Iii, Birmingham, AL 35205-1612 | |
| (205) 939-4512 | |
| (205) 939-4519 |
| Full Name | Dr Janet Cash |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 31 Years |
| Location | 833 Saint Vincents Dr Ste 300, Birmingham, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356315568 | NPI | - | NPPES |
| 051039853 | Other | AL | BCBS PROVIDER NUMBER |
| 000039853 | Medicaid | AL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207NP0225X | Dermatology - Pediatric Dermatology | MD00018343 (Alabama) | Secondary |
| 207NS0135X | Dermatology - Procedural Dermatology | MD00018343 (Alabama) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southview Medical Group, Pc | 8729979794 | 40 |
News Archive
Ethicon, Inc., announced today that the CDC has reviewed clinical data from patients treated with BIOPATCH Protective Disk with CHG as part of its update to the 2002 guidelines for reducing risk of intravascular catheter-associated infections in the United States. In the new guidelines, use of a CHG sponge dressing is designated as a Category 1B recommendation.
As you decide what to get dad for Father's Day, you might want to consider what he gave you when you were conceived. If he smoked, your genes are likely damaged, and your odds for cancers and other diseases throughout your life could be increased. A new research report appearing online in the FASEB Journal, scientists show for the first time in humans that men who smoke before conception can damage the genetic information of their offspring.
Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced the start of a U.S. Phase I clinical trial of its biosimilar erythropoietin (EPO) in patients with renal (kidney) dysfunction who have anemia, an important step on the road toward introducing a biosimilar product in the United States. Erythropoietin is a treatment for anemia associated with chronic renal failure and chemotherapy.
Idera Pharmaceuticals, Inc., today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon Merck KGaA's initiation of a Phase 1b clinical trial of IMO-2055 (EMD 1201081), an agonist of Toll-like Receptor 9 (TLR9), in combination with cisplatin, fluorouracil and cetuximab (Erbitux®) in first-line treatment of patients with squamous cell carcinoma of the head and neck (SCCHN).
› Verified 3 days ago
| Entity Name | Southview Medical Group, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801860333 PECOS PAC ID: 8729979794 Enrollment ID: O20040322000490 |
News Archive
Ethicon, Inc., announced today that the CDC has reviewed clinical data from patients treated with BIOPATCH Protective Disk with CHG as part of its update to the 2002 guidelines for reducing risk of intravascular catheter-associated infections in the United States. In the new guidelines, use of a CHG sponge dressing is designated as a Category 1B recommendation.
As you decide what to get dad for Father's Day, you might want to consider what he gave you when you were conceived. If he smoked, your genes are likely damaged, and your odds for cancers and other diseases throughout your life could be increased. A new research report appearing online in the FASEB Journal, scientists show for the first time in humans that men who smoke before conception can damage the genetic information of their offspring.
Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced the start of a U.S. Phase I clinical trial of its biosimilar erythropoietin (EPO) in patients with renal (kidney) dysfunction who have anemia, an important step on the road toward introducing a biosimilar product in the United States. Erythropoietin is a treatment for anemia associated with chronic renal failure and chemotherapy.
Idera Pharmaceuticals, Inc., today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon Merck KGaA's initiation of a Phase 1b clinical trial of IMO-2055 (EMD 1201081), an agonist of Toll-like Receptor 9 (TLR9), in combination with cisplatin, fluorouracil and cetuximab (Erbitux®) in first-line treatment of patients with squamous cell carcinoma of the head and neck (SCCHN).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Janet Cash, MD 833 Saint Vincents Dr Ste 300, Pob Iii, Birmingham, AL 35205-1612 Ph: (205) 939-4512 | Dr Janet Cash, MD 833 Saint Vincents Dr Ste 300, Pob Iii, Birmingham, AL 35205-1612 Ph: (205) 939-4512 |
News Archive
Ethicon, Inc., announced today that the CDC has reviewed clinical data from patients treated with BIOPATCH Protective Disk with CHG as part of its update to the 2002 guidelines for reducing risk of intravascular catheter-associated infections in the United States. In the new guidelines, use of a CHG sponge dressing is designated as a Category 1B recommendation.
As you decide what to get dad for Father's Day, you might want to consider what he gave you when you were conceived. If he smoked, your genes are likely damaged, and your odds for cancers and other diseases throughout your life could be increased. A new research report appearing online in the FASEB Journal, scientists show for the first time in humans that men who smoke before conception can damage the genetic information of their offspring.
Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced the start of a U.S. Phase I clinical trial of its biosimilar erythropoietin (EPO) in patients with renal (kidney) dysfunction who have anemia, an important step on the road toward introducing a biosimilar product in the United States. Erythropoietin is a treatment for anemia associated with chronic renal failure and chemotherapy.
Idera Pharmaceuticals, Inc., today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon Merck KGaA's initiation of a Phase 1b clinical trial of IMO-2055 (EMD 1201081), an agonist of Toll-like Receptor 9 (TLR9), in combination with cisplatin, fluorouracil and cetuximab (Erbitux®) in first-line treatment of patients with squamous cell carcinoma of the head and neck (SCCHN).
› Verified 3 days ago
Callie Roberts Hill, Dermatology Medicare: Medicare Enrolled Practice Location: 1927 1st Ave N, Birmingham, AL 35203 Phone: 205-933-0987 Fax: 205-930-1750 | |
Carly Elston, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 500 22nd St S, Birmingham, AL 35233 Phone: 205-934-9999 | |
Tiffany Mayo, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1717 6th Ave S, Birmingham, AL 35233 Phone: 800-822-8816 | |
Daniel Bergman, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 619 19th St S, Birmingham, AL 35249 Phone: 205-934-4011 Fax: 205-297-9411 | |
Carlton Phillips, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2100 16th Ave S, Birmingham, AL 35205 Phone: 205-933-0987 Fax: 205-930-1758 | |
Katherine Flanagan, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 813 Shades Creek Pkwy, Suite 205, Birmingham, AL 35209 Phone: 205-578-1799 Fax: 205-578-3158 | |
Vijay Balakrishnan, MD Dermatology Medicare: Medicare Enrolled Practice Location: 510 20th St S Ste 858, Birmingham, AL 35233 Phone: 205-934-5188 |